Literature DB >> 27264584

The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile.

Erkan Yılmaz1, Şükrü Güleç, Didem Torun, İbrahim Celalettin Haznedaroğlu, Nejat Akar.   

Abstract

OBJECTIVE: Ankaferd® Blood Stopper (ABS) is an herbal extract that has historically been used as a hemostatic agent in traditional Turkish medicine. ABS is comprised of a standardized herbal mixture of T. vulgaris, G. glabra, V. vinifera, A. officinarum, and U. dioica. ABS's basic mechanism of action is the formation of an encapsulated protein web, which represents the focal point for vital erythrocyte masses. The hemostatic effects of ABS have been observed in vitro and in vivo. ABS was registered as a hemostatic agent for external hemorrhages and dental bleeding following phase I randomized, double-blind crossover placebo-controlled clinical research, and safety and efficacy reports. In terms of the potential use of ABS, transcription factors may be novel factors that play a role in the hemostatic and other pleiotropic effects of ABS.
METHODS: Hence, the present study aimed to investigate the effects of ABS on endothelium, and possible transcription factor changes in HUVEC (human umbilical vein endothelial cells) and the erythrocyte membrane profile. ABS (5 μL and 50 μL) was administered to HUVEC (in 75 cm2; ~75% fullness) for 5 min and 15 min.
RESULTS: ABS caused significant increases in the level of activation of the following transcription factors; AP2, AR, CRE/ATF1, CREB, E2F1-5, E2F6, EGR, GATA, HNF-1, ISRE, Myc-Max, NF-1, NFkB, p53, PPAR, SMAD 2/3, SP1, TRE/AP1, and YY1. Following erythrocyte membrane isolation, protein complexes were undissolved, but denatured. The protein complex formed was resistant to heat and detergent. Trypsin and sonication were used in order to break this complex; the complex dissolved and erythrocyte membrane proteins were released in SDS-PAGE.
CONCLUSION: ABS established a very fast and solid protein web, and increased the level of transcription factor activation. Therefore the cellular effects of ABS could be related to different intracellular biological pathways.

Entities:  

Year:  2011        PMID: 27264584     DOI: 10.5152/tjh.2011.39

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


  8 in total

1.  Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids.

Authors:  Ahmet Koluman; Nejat Akar; Umit Y Malkan; Ibrahim C Haznedaroglu
Journal:  Biomed Res Int       Date:  2016-01-26       Impact factor: 3.411

2.  Endothelial Cells, Ankaferd Hemostat, and Estradiol.

Authors:  Yasemin Ardıçoğlu; Nejat Akar; İbrahim Haznedaroğlu
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

Review 3.  Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Authors:  Cem Simsek; Sebnem Selek; Meltem Koca; Ibrahim Celal Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-07-27

4.  Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines.

Authors:  Seyhan Turk; Umit Yavuz Malkan; Mehdi Ghasemi; Helin Hocaoglu; Duygu Mutlu; Gursel Gunes; Salih Aksu; Ibrahim Celalettin Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-02-10

5.  Devices for endoscopic hemostasis of nonvariceal GI bleeding (with videos).

Authors:  Mansour A Parsi; Allison R Schulman; Harry R Aslanian; Manoop S Bhutani; Kuman Krishnan; David R Lichtenstein; Joshua Melson; Udayakumar Navaneethan; Rahul Pannala; Amrita Sethi; Guru Trikudanathan; Arvind J Trindade; Rabindra R Watson; John T Maple
Journal:  VideoGIE       Date:  2019-06-27

Review 6.  Antineoplastic Effects of Ankaferd Hemostat.

Authors:  Umit Yavuz Malkan; Ibrahim Celalettin Haznedaroglu
Journal:  Biomed Res Int       Date:  2022-08-02       Impact factor: 3.246

7.  Generation of Chimeric "ABS Nanohemostat" Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model.

Authors:  Emre Huri; Yavuz Beyazit; Rashad Mammadov; Sila Toksoz; Ayse B Tekinay; Mustafa O Guler; Huseyin Ustun; Murat Kekilli; Mumtaz Dadali; Tugrul Celik; Müzeyyen Astarci; Ibrahim C Haznedaroglu
Journal:  Int J Biomater       Date:  2013-02-20

8.  Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.

Authors:  Fatma Beyazit; Yavuz Beyazit; Alpaslan Tanoglu; Ibrahim C Haznedaroglu
Journal:  Med Hypotheses       Date:  2020-07-31       Impact factor: 1.538

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.